Filing Flows › ELI Lilly (LLY) › Other oncology revenue
ELI Lilly (LLY) Other oncology revenue by quarter
ELI Lilly's Other oncology revenue was $1.1B in Q3 2026 (third quarter 2026), -0.6% from Q2 2026. Over the last 6 quarters it ranged from $789M (Q1 2025) to $1.1B (Q2 2026).
| Quarter | Other oncology revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $1.1B | -0.6% | +16% |
| Q2 2026 | $1.1B | +13% | +19% |
| Q1 2026 | $966M | +3% | +22% |
| Q3 2025 | $937M | +1% | — |
| Q2 2025 | $924M | +17% | — |
| Q1 2025 | $789M | — | — |
Q3 2026 at a glance
ELI Lilly, Q3 2026: revenue $24.4B (+39% year over year), operating margin 34.5%, net earnings $6.5B, operating cash flow $11.4B. The chart follows the revenue to costs, profit and cash.
Questions
What is ELI Lilly's Other oncology revenue?
ELI Lilly's Other oncology revenue was $1.1B in Q3 2026 (third quarter 2026), -0.6% from Q2 2026.
How has ELI Lilly's Other oncology revenue changed?
Over the last 6 quarters it ranged from $789M (Q1 2025) to $1.1B (Q2 2026).